"The agreement between Pfizer and Biotie dates back to late 2006, marking the start of Pfizer's financial support for Biotie's PDE10 phosphodiesterase 10 inhibitor research activities. With exclusive authority to develop discovered compounds, Pfizer's pivotal role underscores its commitment to advancing innovative treatments and signifies a positive outlook for the development of potential breakthroughs in this program."